Cantor Fitzgerald sets USD 120.00 target for Vaxcyte stock

Published on 10/17/2026 at 19:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter earnings per share showed a USD 1.97 loss. Vaxcyte stock costs USD 63.62 on October 16, 2026, down 2.53 percent versus its prior close.

October 12 target update

Cantor Fitzgerald initiated a USD 120.00 target on October 12, 2026.
Second-quarter earnings per share showed a USD 1.97 loss against a USD 2.06 consensus loss.
Vaxcyte stock costs USD 63.62 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 2.53 percent from the October 15 close of USD 65.27.
Vaxcyte is scheduled to report its next results on November 3, 2026.

PCVX, US92243G1085, Illustration mit AI erstellt.

On October 12, 2026, Cantor Fitzgerald initiated a USD 120.00 target for Vaxcyte while maintaining an Overweight rating, according to Investing.com. The target stands 88.62 percent above the Nasdaq price of USD 63.62 on October 16, 2026. Vaxcyte stock closed at USD 63.62 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 2.53 percent from the October 15 close of USD 65.27.

What does the target imply?

The target leaves a wide gap between the latest close and Cantor Fitzgerald's valuation. The firm cited updated assumptions after Vaxcyte's OPUS-1 results and subsequent financing, while also pointing to near-term financing pressure and the expected timing of pediatric data, Investing.com reported on October 12, 2026.

Quarterly loss beats expectations

Vaxcyte reported a second-quarter 2026 loss of USD 1.97 per diluted share, compared with a consensus loss of USD 2.06 and a prior-year loss of USD 1.22, according to MarketBeat on October 7, 2026. The result was better than the consensus loss by USD 0.09 per share.

Stock remains below its high

At USD 63.62, the stock stood 29.90 percent below its 52-week high of USD 90.75 and 59.60 percent above its 52-week low of USD 39.87 on October 16, 2026. The stock was up 37.90 percent year to date, while its market capitalization was USD 10.0 billion. Vaxcyte is scheduled to report its next results on November 3, 2026, according to MetaCap.

Comparison with peers

Vaxcyte (Nasdaq, USD): minus 2.53 percent, market capitalization USD 9.8 billion

Pfizer (NYSE, USD): plus 0.48 percent, P/E 39.09, market capitalization USD 168.6 billion

GSK (NYSE, USD): plus 1.00 percent, P/E 15.65, market capitalization USD 99.2 billion

Price and upcoming date

Vaxcyte's latest session left the stock below its October 5 high, even as the year-to-date gain remained 37.90 percent. The next scheduled reporting date is November 3, 2026.

The closing price was USD 63.62 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 2.53 percent from the October 15 close of USD 65.27.